Open Access

BOOK REVIEW

Karl Pang
Canadian Journal of Urology, Vol.31, No.4, pp. 11914-11914, 2024
Abstract This article has no abstract. More >

View

49

Download

56

Open Access

EDITORIAL

Leonard G. Gomella
Canadian Journal of Urology, Vol.31, No.4, pp. 11915-11915, 2024
Abstract This article has no abstract. More >

View

59

Download

54

Open Access

LEGENDS IN UROLOGY

Jerry G. Blaivas
Canadian Journal of Urology, Vol.31, No.4, pp. 11916-11920, 2024
Abstract This article has no abstract. More >

View

52

Download

45

Open Access

REVIEW

Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester
Canadian Journal of Urology, Vol.31, No.4, pp. 11921-11930, 2024
Abstract Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.
Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference… More >

View

45

Download

36

Open Access

ARTICLE

Bárbara Vieira Lima Aguiar Melão¹, Sabrina Thalita dos Reis Faria², Kátia Ramos Moreira Leite², Ruan César Aparecido Pimenta², Miguel Srougi¹, Alberto Azoubel Antunes¹
Canadian Journal of Urology, Vol.31, No.4, pp. 11931-11940, 2024
Abstract Introduction: Prostate cancer has a variable natural history and, despite the existence of biochemical recurrence (BCR) predictors, they are still limited in predicting outcomes. The role of testosterone in advanced prostate cancer is well known, however its role in localized prostate cancer is still uncertain. In the present study, we evaluated the relationship of testosterone levels and androgen receptor (AR) expression with oncological and functional outcomes, in patients undergoing radical retropubic prostatectomy (RRP).
Materials and methods: Through a retrospective study, patients who underwent RRP, who had at least two preoperative total testosterone dosages, were analyzed and compared… More >

View

65

Download

51

Open Access

COMMENTARY

Judd W. Moul
Canadian Journal of Urology, Vol.31, No.4, pp. 11941-11942, 2024
Abstract This article has no abstract. More >

View

65

Download

47

Open Access

ARTICLE

Roseanne Ferreira¹, Emad Alwashmi^1,2, Samuel Otis-Chapados¹, Naeem Bhojani³, Kevin C. Zorn⁴, Bilal Chughtai⁵, Dean S. Elterman¹
Canadian Journal of Urology, Vol.31, No.4, pp. 11943-11949, 2024
Abstract Introduction: Despite the growing body of literature on sacral neuromodulation (SNM) outcomes, research focusing on male patients remains limited and often represented by small cohorts nested within a larger study of mostly women. Herein, we evaluated the outcomes of SNM in a male-only cohort with overactive bladder (OAB), fecal incontinence (FI), chronic bladder pain, and neurogenic lower urinary tract dysfunction (NLUTD).
Materials and methods: This retrospective cohort study included 64 male patients who underwent SNM insertion between 2013 and 2021 at a high-volume tertiary center. Indications for SNM therapy included OAB, FI, chronic pelvic pain, and NLUTD.… More >

View

52

Download

42

Open Access

ARTICLE

Hope Ogbeide^1,3, Ehidiamen Oamen¹, Travis H. Wilmore¹, Jennifer D. Peck^1,2, Johnathan P. Doolittle¹, Nathan A. Bradley¹, Jonathan E. Heinlen¹
Canadian Journal of Urology, Vol.31, No.4, pp. 11950-11954, 2024
Abstract Introduction: In May 2022, lawmakers in Oklahoma passed House Bill 4327, which outlawed abortion after fertilization. The governor signed the bill on May 25, 2022. It is uncertain whether these changes will motivate more men in Oklahoma to undergo vasectomy.
Materials and methods: Males seeking vasectomy were informed of the study and asked to participate. Participants filled out a survey regarding their marital status, number of children, fertility treatment history, and their influences in making the decision to pursue vasectomy. We removed the identifying information from the survey. After collection, the data was imported to a database.… More >

View

63

Download

46

Open Access

ARTICLE

Snir Dekalo^1,2, Ohad Mazliah², Eyal Barkai^1,2, Yuval Bar-Yosef^1,2, Haim Herzberg^1,2, Tomer Bashi^1,2, Ibrahim Fahoum^2,3, Sophie Barnes^2,4, Mario Sofer^1,2, Ofer Yossepowitch^1,2, Gal Keren-Paz^1,2, Roy Mano^1,2
Canadian Journal of Urology, Vol.31, No.4, pp. 11955-11962, 2024
Abstract Introduction: Most men diagnosed with very-low and low-risk prostate cancer are candidates for active surveillance; however, there is still a misclassification risk. We examined whether PI-RADS category 4 or 5 combined with ISUP 1 on prostate biopsy predicts upgrading and/ or adverse pathology at radical prostatectomy.
Materials and methods: A total of 127 patients had ISUP 1 cancer on biopsy after multiparametric MRI (mpMRI) and then underwent radical prostatectomy. We then evaluated them for ISUP upgrading and/or adverse pathology on radical prostatectomy.
Results: Eight-nine patients (70%) were diagnosed with PI-RADS 4 or 5 lesions. ISUP upgrading was significantly… More >

View

46

Download

39

Open Access

ARTICLE

Bassem Toeama¹, Nathan Perlis², Paul Grootendorst¹, William Orovan³, Emmanuel Papadimitropoulos^1,4
Canadian Journal of Urology, Vol.31, No.4, pp. 11963-11970, 2024
Abstract Introduction: Prostate cancer is the third leading cause of death from cancer among Canadian men. High intensity focused ultrasound (HIFU) is a novel approach for primary treatment of localized prostate cancer. Little is known, however, about its costs. We aimed to collect the direct costs and health-related quality of life (HRQoL) data of HIFU in primary treatment of localized low and intermediate risk prostate cancer in Ontario.
Materials and methods: We collected direct costs and HRQoL data of 20 patients with localized low or intermediate risk prostate cancer who received whole gland HIFU at a privately owned… More >

View

64

Download

48